These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23320098)

  • 1. Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines.
    Teixidó C; Marés R; Aracil M; Ramón y Cajal S; Hernández-Losa J
    PLoS One; 2013; 8(1):e53645. PubMed ID: 23320098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
    Teixidó C; Arguelaguet E; Pons B; Aracil M; Jimeno J; Somoza R; Marés R; Ramón Y Cajal S; Hernández-Losa J
    Int J Oncol; 2012 Jul; 41(1):317-24. PubMed ID: 22485250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.
    Serova M; de Gramont A; Bieche I; Riveiro ME; Galmarini CM; Aracil M; Jimeno J; Faivre S; Raymond E
    Mar Drugs; 2013 Mar; 11(3):944-59. PubMed ID: 23519149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
    Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Corominas-Faja B; Cufí S; Vazquez-Martin A; Martin-Castillo B; Iglesias JM; López-Bonet E; Martin ÁG; Menendez JA
    Cell Cycle; 2012 Nov; 11(21):4020-32. PubMed ID: 22992620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
    Martins CD; Da Pieve C; Burley TA; Smith R; Ciobota DM; Allott L; Harrington KJ; Oyen WJG; Smith G; Kramer-Marek G
    Clin Cancer Res; 2018 Apr; 24(8):1853-1865. PubMed ID: 29437790
    [No Abstract]   [Full Text] [Related]  

  • 11. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
    Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
    Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
    Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
    Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial to mesenchymal transition is associated with rapamycin resistance.
    Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
    Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
    Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
    Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.
    Li X; Duan Y; Qiao C; Zhou T; Yu M; Geng J; Feng J; Shen B; Lv M; Li Y
    Technol Cancer Res Treat; 2016 Aug; 15(4):573-82. PubMed ID: 26041400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment.
    Váradi T; Roszik J; Lisboa D; Vereb G; Molina-Guijarro JM; Galmarini CM; Szöllosi J; Nagy P
    Eur J Pharmacol; 2011 Sep; 667(1-3):91-9. PubMed ID: 21658382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism.
    Yang QL; Zhang LY; Wang HF; Li Y; Wang YY; Chen TT; Dai MF; Wu HH; Chen SL; Wang WR; Wu Q; Chen CJ; Zhou CZ
    Oncotarget; 2017 Jun; 8(23):37448-37463. PubMed ID: 28415580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition.
    Shi RZ; He YF; Wen J; Niu YN; Gao Y; Liu LH; Zhang XP; Wang Y; Zhang XL; Zhang HF; Chen M; Hu XL
    Cell Biol Int; 2021 Aug; 45(8):1644-1653. PubMed ID: 33760350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.
    Wehrenberg-Klee E; Sinevici N; Nesti S; Kalomeris T; Austin E; Larimer B; Mahmood U
    Mol Imaging Biol; 2021 Dec; 23(6):930-940. PubMed ID: 34101105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.
    Thomas C; Rajapaksa G; Nikolos F; Hao R; Katchy A; McCollum CW; Bondesson M; Quinlan P; Thompson A; Krishnamurthy S; Esteva FJ; Gustafsson JÅ
    Breast Cancer Res; 2012 Nov; 14(6):R148. PubMed ID: 23158001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.